Article
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Clinical immunology (Orlando, Fla.) - 1 Feb 2016
McKay Fiona C, Gatt Prudence N, Fewings Nicole, Parnell Grant P, Schibeci Stephen D, Basuki Monica A I, Powell Joseph E, Goldinger Anita, Fabis-Pedrini Marzena J, Kermode Allan G, Burke Therese, Vucic Steve, Stewart Graeme J, Booth David R
Abstract excerpt
Multiple Sclerosis (MS) is an autoimmune disease treated by therapies targeting peripheral blood cells. We previously identified that expression of two MS-risk genes, the transcription factors EOMES and TBX21 (ET), was low in blood from MS and stable over time. Here we replicated the low ET expression in a new MS cohort (p<0.0007 for EOMES, p<0.028 for TBX21) and demonstrate longitudinal stability (p<10(-4)) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.